<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36375693</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>13</EndPage><MedlinePgn>10-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2022.11.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(22)00596-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to describe post-acute sequelae of SARS-CoV-2 infection (PASC) related symptoms 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brunvoll</LastName><ForeName>Sonja H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: shbrunvoll@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygaard</LastName><ForeName>Anders B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: anders.b.nygaard@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagerland</LastName><ForeName>Morten W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: m.w.fagerland@medisin.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Petter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: petter.holland@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellingjord-Dale</LastName><ForeName>Merete</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: mellingjord@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>John Arne</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: j.a.dahl@medisin.uio.no.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;raas</LastName><ForeName>Arne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: arne@meg.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>14</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36375693</ArticleId><ArticleId IdType="pmc">PMC9651990</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2022.11.009</ArticleId><ArticleId IdType="pii">S1201-9712(22)00596-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328:676&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>European Observatory on Health Systems and Policies, Rajan S, Khunti K, Alwan N, Steves C, Greenhalgh T.  World Health Organization. Regional Office for Europe.; 2021. In the Wake of the Pandemic: preparing for Long COVID 2021.https://apps.who.int/iris/handle/10665/339629 accessed 15th August, 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">33877759</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Vanichkachorn GS, Munipalli B, Hanson SN, Abu Dabrh AM, Croghan IT, et al. Postacute sequelae of SARS-CoV-2 infection-lessons learned from a coordinated health system response. Mayo Clin Proc Innov Qual Outcomes. 2022;6:311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9156955</ArticleId><ArticleId IdType="pubmed">35669936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjetland EF, Kalleberg KT, S&#xf8;raas CL, Hammarstr&#xf6;m B, Myklebust T&#xc5;, Jenum S, et al.  Risk factors for community transmission of SARS-CoV-2. A cross-sectional study in 116,678 people. medRxiv. 2020;24 https://www.medrxiv.org/content/10.1101/2020.12.23.20248514v1.full December. accessed 15th August, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.23.20248514v1.full</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA, et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022;7:101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411827</ArticleId><ArticleId IdType="pubmed">36028498</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>